NRx ended 2025 with $7.8 million in cash on hand, eliminated all convertible debt from its balance sheet, and expects—based on growing clinic revenues and its at-the-market (ATM) activity—to have sufficient resources to fund operations through at least the end of 2026, according to management.Founder, Chairman, and CEO Dr. Jonathan Javitt said the company is pursuing “three potential drug approvals” in the near term, while building out HOPE Therapeutics’ clinic network. He added that HOPE clinics are “demon ...